Cargando…

CAR-T-Cell Therapy for Solid Tumors Positive for Fibronectin Extra Domain B

(1) Background: The lack of specific targets has slowed the progress of CAR-T in treating solid tumors. Recent studies have revealed that EDB-FN (fibronectin extra domain B) may be an effective target for CAR-T treatment of solid tumors; EDB-FN is expressed in tumor and embryonic tissues, and antibo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Zhijie, Liu, Chang, Yang, Zhe, Yin, Hongping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496916/ https://www.ncbi.nlm.nih.gov/pubmed/36139437 http://dx.doi.org/10.3390/cells11182863

Ejemplares similares

Treating solid tumors with TCR-based chimeric antigen receptor targeting extra domain B-containing fibronectin
por: Zhang, Zhijie, et al.
Publicado: (2023)

Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells
por: Martín-Otal, Celia, et al.
Publicado: (2022)

Correction: Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells
Publicado: (2022)

Human fibronectin extra domain B as a biomarker for targeted therapy in cancer
por: Lieverse, Relinde I. Y., et al.
Publicado: (2020)

MRI of Breast Tumor Initiating Cells Using the Extra Domain-B of Fibronectin Targeting Nanoparticles
por: Sun, Yujin, et al.
Publicado: (2014)

Expression of Fibronectin Isoforms in Human Breast Tissue: Production of Extra Domain A(+)/Extra Domain B(+) by Cancer Cells and Extra Domain A(+) by Stromal Cells
por: Matsumoto, Ei‐ichi, et al.
Publicado: (1999)

Gene editing of the extra domain A positive fibronectin in various tumors, amplified the effects of CRISPR/Cas system on the inhibition of tumor progression
por: Lv, Wan-Qi, et al.
Publicado: (2017)

Fibronectin Extra Domain A Promotes Liver Sinusoid Repair following Hepatectomy
por: Sackey-Aboagye, Bridget, et al.
Publicado: (2016)

Anti-Extra Domain B Splice Variant of Fibronectin Antibody–Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade
por: Hooper, Andrea T., et al.
Publicado: (2022)

Lack of Fibronectin Extra Domain A Alternative Splicing Exacerbates Endothelial Dysfunction in Diabetes
por: Gortan Cappellari, Gianluca, et al.
Publicado: (2016)

CAR-T Therapies in Solid Tumors: Opportunities and Challenges
por: Guzman, Grace, et al.
Publicado: (2023)

CAR T-Cell Therapy in Children with Solid Tumors
por: Kulczycka, Marika, et al.
Publicado: (2023)

Extra-domain B of fibronectin as an alternative target for drug delivery and a cancer diagnostic and prognostic biomarker for malignant glioma
por: Saw, Phei Er, et al.
Publicado: (2021)

Expression of extra domain A fibronectin sequence in vascular smooth muscle cells is phenotype dependent
Publicado: (1989)

Fibroblast-like synovial cell production of extra domain A fibronectin associates with inflammation in osteoarthritis
por: Kragstrup, Tue W., et al.
Publicado: (2019)

Fibronectin extra domain a limits liver dysfunction and protects mice during acute inflammation()
por: Venu, Vivek Krishna Pulakazhi, et al.
Publicado: (2023)

Alternative Splicing of the Angiogenesis Associated Extra-Domain B of Fibronectin Regulates the Accessibility of the B-C Loop of the Type III Repeat 8
por: Ventura, Elisa, et al.
Publicado: (2010)

Mesothelin-targeted CAR-T cells for adoptive cell therapy of solid tumors
por: Zhang, Gui-Zhen, et al.
Publicado: (2019)

Current Progress in CAR-T Cell Therapy for Solid Tumors
por: Ma, Shuo, et al.
Publicado: (2019)

Hurdles to breakthrough in CAR T cell therapy of solid tumors
por: Marofi, Faroogh, et al.
Publicado: (2022)

Clinical Investigations of CAR-T Cell Therapy for Solid Tumors
por: Chen, Kun, et al.
Publicado: (2022)

Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models
por: El-Emir, E, et al.
Publicado: (2007)

Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers
por: Nguyen, Martin V., et al.
Publicado: (2020)

Fibronectin extra domain A (FN-EDA) causes glaucomatous trabecular meshwork, retina, and optic nerve damage in mice
por: Mavlyutov, Timur A., et al.
Publicado: (2022)

Innovative CAR-T Cell Therapy for Solid Tumor; Current Duel between CAR-T Spear and Tumor Shield
por: Jo, Yuna, et al.
Publicado: (2020)

Fibronectin containing alternatively spliced extra domain A interacts at the central and c-terminal domain of Toll-like receptor-4
por: Gupta, Shubhangi, et al.
Publicado: (2022)

CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies
por: Knochelmann, Hannah M., et al.
Publicado: (2018)

CAR T cell therapy in solid tumors: a short review
por: Umut, Öykü, et al.
Publicado: (2021)

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors
por: Boccalatte, Francesco, et al.
Publicado: (2022)

Combining chemotherapy with CAR-T cell therapy in treating solid tumors
por: Wang, Arthur Xuan, et al.
Publicado: (2023)

Nanoparticles targeting extra domain B of fibronectin-specific to the atherosclerotic lesion types III, IV, and V-enhance plaque detection and cargo delivery
por: Yu, Mikyung, et al.
Publicado: (2018)

Cellular Fibronectin Containing Extra Domain A Causes Insulin Resistance via Toll-like Receptor 4
por: Rajak, Sangam, et al.
Publicado: (2020)

Rationally designed approaches to augment CAR-T therapy for solid tumor treatment
por: Zhu, Chaojie, et al.
Publicado: (2023)

Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology
por: Watanabe, Keisuke, et al.
Publicado: (2018)

Combination therapy: A feasibility strategy for CAR-T cell therapy in the treatment of solid tumors
por: Xu, Jinjing, et al.
Publicado: (2018)

Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy
por: Chung, Hyunmin, et al.
Publicado: (2021)

Bright future or blind alley? CAR-T cell therapy for solid tumors
por: Zhang, Kai, et al.
Publicado: (2023)

CAR T Cell Locomotion in Solid Tumor Microenvironment
por: Nguyen, Duy T., et al.
Publicado: (2022)

Fibronectin extra domain A (FN-EDA) elevates intraocular pressure through Toll-like receptor 4 signaling
por: Roberts, Amanda L., et al.
Publicado: (2020)

Efficiency of CAR-T Therapy for Treatment of Solid Tumor in Clinical Trials: A Meta-Analysis
por: Hou, Bin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_l2agmlcjqhbpa2q8l9i13t619f